NCT04077515View on ClinicalTrials.gov

Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 10, 2022

Study Completion Date

December 31, 2022

Conditions
HemangiomaKaposiform Hemangioendothelioma
Interventions
DRUG

Sirolimus(0.8mg/m2)

The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.

DRUG

Sirolimus(0.7mg/m2)

The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.

Trial Locations (1)

210012

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER

NCT04077515 - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma | Biotech Hunter | Biotech Hunter